DuoPlavin (Clopidogrel + Aspirin)
Dual antiplatelet combination therapy for prevention of atherothrombotic events
Quick Facts About DuoPlavin
Key Takeaways About DuoPlavin
- Combination therapy in one tablet: DuoPlavin combines clopidogrel and aspirin, two proven antiplatelet agents, into a single film-coated tablet to simplify daily medication
- Used for serious cardiovascular conditions: Prescribed after acute coronary syndrome, coronary stent placement, or recent heart attack to prevent further atherothrombotic events
- Increased bleeding risk: The main risk is bleeding; report any unusual bruising, blood in stools or urine, or prolonged bleeding from cuts to your doctor immediately
- Do not stop abruptly: Never stop taking DuoPlavin without consulting your doctor, as sudden discontinuation can significantly increase the risk of heart attack or stent thrombosis
- Important drug interactions: Avoid omeprazole, esomeprazole, ibuprofen, and other NSAIDs as they can reduce the effectiveness of DuoPlavin or increase bleeding risk
What Is DuoPlavin and What Is It Used For?
DuoPlavin is a prescription combination medicine containing clopidogrel (75 mg) and acetylsalicylic acid, commonly known as aspirin (75 mg). It is used to prevent blood clots (atherothrombotic events) in adults who are already taking both of these medicines separately for conditions such as acute coronary syndrome, recent heart attack, or after coronary stent placement.
DuoPlavin belongs to a class of medicines called antiplatelet agents. Platelets are small cell fragments in your blood that clump together during normal blood clotting. In people with certain cardiovascular conditions, platelets can form unwanted clots inside arteries that have been damaged by atherosclerosis (a build-up of fatty deposits). These clots can block blood flow to the heart (causing a heart attack) or to the brain (causing a stroke).
The two active substances in DuoPlavin work through different but complementary mechanisms to prevent dangerous blood clots. Clopidogrel is a thienopyridine that irreversibly blocks the P2Y12 adenosine diphosphate (ADP) receptor on the surface of platelets, preventing them from activating and aggregating. Aspirin (acetylsalicylic acid) irreversibly inhibits the enzyme cyclooxygenase-1 (COX-1), reducing the production of thromboxane A2, another powerful activator of platelet aggregation. Together, they target two key pathways of platelet activation, providing more comprehensive protection than either drug alone.
This approach is known as dual antiplatelet therapy (DAPT), and it has been shown in landmark clinical trials such as CURE (Clopidogrel in Unstable Angina to Prevent Recurrent Events) and COMMIT (Clopidogrel and Metoprolol in Myocardial Infarction Trial) to significantly reduce the risk of major cardiovascular events including heart attack, stroke, and cardiovascular death compared to aspirin alone.
Approved Indications
DuoPlavin is specifically indicated for the prevention of atherothrombotic events in adult patients already taking both clopidogrel and aspirin. It is intended as a substitution therapy for convenience and is not used to initiate dual antiplatelet treatment. Common clinical scenarios where DuoPlavin may be prescribed include:
- Acute coronary syndrome (ACS): Including non-ST-segment elevation myocardial infarction (NSTEMI) and unstable angina, whether managed medically or with percutaneous coronary intervention (PCI) with or without stent placement
- ST-elevation myocardial infarction (STEMI): In patients who are eligible for thrombolytic therapy or managed conservatively
- After coronary stent placement: Both drug-eluting stents (DES) and bare-metal stents (BMS) require a period of dual antiplatelet therapy to prevent stent thrombosis, a rare but potentially fatal complication
DuoPlavin is not meant to start dual antiplatelet therapy. Your doctor will first prescribe clopidogrel and aspirin as separate tablets to find the right doses and ensure you tolerate both medicines. Once you are stabilized, they may switch you to DuoPlavin for convenience. Always follow your doctor's instructions regarding when and how to make this switch.
What Should You Know Before Taking DuoPlavin?
Before taking DuoPlavin, inform your doctor about all medical conditions, especially bleeding disorders, liver problems, kidney disease, history of stomach ulcers, and any upcoming surgery. DuoPlavin should not be taken during pregnancy, and it is important to disclose all medications you are currently taking, including over-the-counter drugs and supplements.
Contraindications
You must not take DuoPlavin if any of the following apply to you:
- Allergy to clopidogrel or aspirin: If you are allergic (hypersensitive) to clopidogrel, acetylsalicylic acid (aspirin), or any of the other ingredients in DuoPlavin. Aspirin allergy includes patients with asthma triggered by salicylates or NSAIDs (aspirin-exacerbated respiratory disease)
- Active pathological bleeding: Such as a bleeding stomach ulcer, bleeding in the brain (intracranial haemorrhage), or any other active bleeding condition
- Severe liver impairment: Patients with severe hepatic dysfunction should not take DuoPlavin as it may affect how the drug is metabolized and increase bleeding risk
- Third trimester of pregnancy: Aspirin in doses above 100 mg/day is contraindicated after week 28 of pregnancy due to risk of premature closure of the ductus arteriosus and prolonged bleeding during delivery
Warnings and Precautions
Talk to your doctor or pharmacist before taking DuoPlavin if any of the following conditions apply:
- History of bleeding or bleeding disorders: DuoPlavin significantly increases the risk of bleeding. You should be aware of the signs of bleeding, including unexplained bruising, blood in stools (which may appear black or tarry), blood in urine, vomiting blood, or prolonged nosebleeds
- Recent surgery or planned procedures: If you need to undergo surgery (including dental procedures), tell your surgeon that you are taking DuoPlavin. You may need to stop taking it 5 to 7 days before the procedure, but only on your doctor's advice. Premature discontinuation after coronary stent placement carries significant risk
- Peptic ulcer disease or gastrointestinal conditions: DuoPlavin increases the risk of gastrointestinal bleeding. Your doctor may prescribe a proton pump inhibitor (PPI), but certain PPIs such as omeprazole and esomeprazole should be avoided as they interfere with clopidogrel activation
- Kidney impairment: Use with caution in patients with renal disease, as aspirin can further reduce kidney function in susceptible individuals
- Gout: Aspirin can increase uric acid levels at low doses, potentially worsening gout
- Glucose-6-phosphate dehydrogenase (G6PD) deficiency: Aspirin may cause haemolysis or haemolytic anaemia in patients with G6PD deficiency
- CYP2C19 poor metabolizers: Clopidogrel is a prodrug that requires activation by liver enzymes, particularly CYP2C19. Patients who are poor metabolizers of CYP2C19 may have reduced antiplatelet response. Genetic testing is available and may be recommended by your doctor
Abruptly stopping dual antiplatelet therapy, especially within the first few months after a coronary stent placement, can dramatically increase the risk of stent thrombosis — a sudden blood clot in the stent that can cause a massive heart attack. If you experience side effects that make you want to stop, speak with your cardiologist first. They can assess your risk and determine the safest approach.
Pregnancy and Breastfeeding
DuoPlavin should generally be avoided during pregnancy. In the third trimester, it is strictly contraindicated due to the aspirin component, which can cause premature closure of the ductus arteriosus in the unborn baby and increase the risk of maternal and fetal bleeding at delivery. In the first and second trimesters, DuoPlavin should only be used if the potential benefit justifies the potential risk to the fetus.
It is not known whether clopidogrel passes into human breast milk. Aspirin does pass into breast milk in small amounts. Because of the potential for adverse effects in nursing infants, a decision should be made whether to discontinue breastfeeding or to discontinue DuoPlavin, taking into account the importance of the medicine to the mother. Consult your doctor for individual guidance.
How Does DuoPlavin Interact with Other Drugs?
DuoPlavin can interact with many medications that affect blood clotting, stomach acid, or liver enzymes. The most important interactions include oral anticoagulants (e.g. warfarin), certain proton pump inhibitors (omeprazole, esomeprazole), NSAIDs (e.g. ibuprofen), and SSRIs. Always inform your doctor and pharmacist about all medicines you are taking.
Drug interactions with DuoPlavin can occur through two main mechanisms: pharmacodynamic interactions (where another drug adds to the bleeding risk) and pharmacokinetic interactions (where another drug interferes with the metabolism and activation of clopidogrel). Understanding these interactions is critical for patient safety, as some can significantly reduce the therapeutic effect of DuoPlavin or dramatically increase the risk of life-threatening bleeding.
Major Interactions
| Drug / Class | Interaction | Clinical Significance |
|---|---|---|
| Warfarin & oral anticoagulants | Additive bleeding risk; triple therapy (DAPT + anticoagulant) significantly increases major bleeding | Avoid if possible; if required, use shortest duration and closely monitor INR and bleeding signs |
| Omeprazole / Esomeprazole | Inhibits CYP2C19, reducing conversion of clopidogrel to its active metabolite by 40-50% | Avoid; use pantoprazole or rabeprazole instead if a PPI is needed (minimal CYP2C19 inhibition) |
| NSAIDs (ibuprofen, naproxen) | Increased risk of GI bleeding; ibuprofen may competitively block aspirin's irreversible COX-1 inhibition | Avoid; use paracetamol (acetaminophen) for pain relief when possible |
| Methotrexate (high dose) | Aspirin reduces renal excretion of methotrexate, increasing plasma levels and toxicity risk | Monitor methotrexate levels closely; avoid high-dose methotrexate with DuoPlavin |
| Thrombolytics (alteplase, tenecteplase) | Greatly increased bleeding risk when combined with dual antiplatelet therapy | Use under specialist supervision only; expected in acute MI setting with careful risk-benefit assessment |
Minor Interactions
| Drug / Class | Interaction | Clinical Significance |
|---|---|---|
| SSRIs (fluoxetine, sertraline, paroxetine) | SSRIs impair serotonin uptake by platelets, adding to bleeding risk; fluoxetine also inhibits CYP2C19 | Monitor for increased bleeding; consider alternative antidepressants with less CYP2C19 inhibition |
| ACE inhibitors | Aspirin may attenuate the vasodilatory and cardioprotective effects of ACE inhibitors at higher doses | Clinically relevant mainly at aspirin doses >300 mg/day; at 75 mg, interaction is minimal |
| Diuretics | Aspirin may reduce the natriuretic effect of diuretics and increase risk of acute kidney injury in dehydrated patients | Ensure adequate hydration; monitor kidney function, especially in elderly patients |
| Morphine & opioids | Opioids slow gastric emptying, delaying and reducing absorption of oral clopidogrel | Consider alternative analgesics when rapid antiplatelet onset is needed, such as in acute MI |
Not all PPIs interact with clopidogrel equally. Omeprazole and esomeprazole are strong CYP2C19 inhibitors and should be avoided. Pantoprazole and rabeprazole have minimal CYP2C19 inhibition and are considered safer alternatives when gastric protection is needed during dual antiplatelet therapy. The ESC and AHA/ACC guidelines recommend pantoprazole as the preferred PPI with clopidogrel.
What Is the Correct Dosage of DuoPlavin?
The standard dose of DuoPlavin is one tablet (clopidogrel 75 mg + aspirin 75 mg) taken once daily by mouth, with or without food. The duration of treatment depends on your condition and is determined by your physician, typically ranging from 1 to 12 months.
DuoPlavin is available in a single strength: each film-coated tablet contains 75 mg of clopidogrel (as clopidogrel hydrogen sulphate) and 75 mg of acetylsalicylic acid (aspirin). The tablet should be swallowed whole with water and can be taken at any time of day, although taking it at the same time each day helps maintain consistent blood levels and improves adherence.
Adults
Standard Dosing
Dose: One DuoPlavin tablet (75 mg/75 mg) once daily.
Note: In acute coronary syndrome, treatment is usually initiated with separate loading doses of clopidogrel (300 mg or 600 mg) and aspirin (150-325 mg) before transitioning to maintenance therapy with DuoPlavin. The loading dose is not covered by DuoPlavin and must be given as separate tablets.
| Indication | Daily Dose | Recommended Duration |
|---|---|---|
| Acute coronary syndrome (NSTEMI/unstable angina) | 1 tablet (75/75 mg) once daily | Up to 12 months (optimal benefit shown at 12 months in CURE trial) |
| STEMI (with or without thrombolysis) | 1 tablet (75/75 mg) once daily | At least 4 weeks (COMMIT trial); up to 12 months per guidelines |
| After drug-eluting stent (DES) | 1 tablet (75/75 mg) once daily | Minimum 6 months; 12 months recommended (ESC 2023) |
| After bare-metal stent (BMS) | 1 tablet (75/75 mg) once daily | Minimum 1 month; 6-12 months is common practice |
Children
DuoPlavin is not recommended for use in children and adolescents under 18 years of age. The safety and efficacy of clopidogrel in combination with aspirin have not been established in the paediatric population. In children who require antiplatelet therapy (for example, after Kawasaki disease or congenital heart procedures), alternative regimens are used under specialist supervision.
Elderly
No dose adjustment is required in elderly patients. However, older adults are at increased risk of bleeding, particularly gastrointestinal bleeding, and should be monitored more closely. The elderly are also more likely to have impaired renal function, which can increase the risk of aspirin-related side effects. Physicians should carefully weigh the benefits of dual antiplatelet therapy against the bleeding risk in patients over 75 years of age.
Missed Dose
If you forget to take your DuoPlavin tablet:
- Within 12 hours of your usual time: Take the missed dose as soon as you remember.
- More than 12 hours late: Skip the missed dose entirely. Take your next dose at the regular scheduled time.
- Never take a double dose to make up for a forgotten tablet, as this increases the risk of bleeding.
If you miss doses frequently, speak to your doctor or pharmacist about strategies to improve adherence, such as using a pill organizer or setting a daily alarm on your phone.
Overdose
Overdose with DuoPlavin may lead to prolonged bleeding time and subsequent bleeding complications. Symptoms of overdose may include vomiting, epigastric pain, gastrointestinal bleeding, tinnitus, dizziness, headache, and confusion. In severe aspirin overdose, hyperventilation, metabolic acidosis, and altered consciousness can occur.
There is no specific antidote for clopidogrel. If rapid reversal of the antiplatelet effect is required, platelet transfusion may be considered. For aspirin overdose, standard supportive measures including gastric lavage (if ingestion was recent) and activated charcoal may be used. If you suspect an overdose, contact your local poison control centre or emergency services immediately.
What Are the Side Effects of DuoPlavin?
Like all medicines, DuoPlavin can cause side effects, although not everybody gets them. The most commonly reported side effects relate to its blood-thinning mechanism and include bleeding events (bruising, nosebleeds, gastrointestinal bleeding), stomach upset, and diarrhoea. Serious but rare side effects include severe bleeding, thrombotic thrombocytopenic purpura (TTP), and severe allergic reactions.
The side effect profile of DuoPlavin reflects the known safety profiles of both clopidogrel and aspirin. Because DuoPlavin inhibits platelet function through two different pathways, the bleeding risk is inherently higher than with either agent alone. Clinical trials such as CURE demonstrated that the addition of clopidogrel to aspirin increased major bleeding from 2.7% to 3.7% over 12 months, but this was outweighed by the significant reduction in cardiovascular events.
Very Common (affects more than 1 in 10 people)
- Easy bruising (ecchymosis)
- Minor bleeding (prolonged bleeding from cuts)
Common (affects 1 to 10 in 100 people)
- Nosebleeds (epistaxis)
- Gastrointestinal bleeding (blood in stools, dark tarry stools)
- Stomach pain, indigestion (dyspepsia)
- Diarrhoea
- Nausea
- Haematoma (collection of blood under the skin)
- Haematuria (blood in urine)
Uncommon (affects 1 to 10 in 1,000 people)
- Headache, dizziness
- Stomach ulcer (gastric or duodenal)
- Vomiting
- Skin rash, itching (pruritus)
- Prolonged bleeding time after procedures
- Decreased platelet count (thrombocytopenia)
- Decreased white blood cell count (leukopenia, neutropenia)
Rare (affects fewer than 1 in 1,000 people)
- Thrombotic thrombocytopenic purpura (TTP) — a serious condition causing blood clots and low platelets
- Severe allergic reactions (anaphylaxis, angioedema)
- Intracranial haemorrhage (bleeding in the brain)
- Severe gastrointestinal haemorrhage
- Aplastic anaemia, pancytopenia
- Hepatitis, acute liver failure
- Serum sickness
- Stevens-Johnson syndrome, toxic epidermal necrolysis
Contact your doctor or go to the nearest emergency department immediately if you experience any of the following: vomiting blood or material that looks like coffee grounds; black, tarry stools; blood in your urine; coughing up blood; unexplained or prolonged bleeding; sudden severe headache; weakness on one side of the body; sudden difficulty speaking; chest pain; or signs of severe allergic reaction (swelling of face, lips, tongue, or throat, difficulty breathing).
How Should You Store DuoPlavin?
Store DuoPlavin at room temperature below 25°C (77°F) in its original packaging to protect from moisture and light. Keep out of reach of children. Do not use after the expiry date printed on the carton and blister pack.
Proper storage of DuoPlavin is important to maintain the effectiveness and safety of the medicine. Follow these guidelines to ensure your medication remains in good condition:
- Temperature: Store below 25°C (77°F). Do not refrigerate or freeze.
- Moisture protection: Keep the tablets in their original blister packaging until you are ready to take them. Do not transfer them to other containers.
- Light protection: Store in the original carton to protect from light exposure.
- Child safety: Keep all medicines out of the sight and reach of children, ideally in a locked medicine cabinet.
- Expiry date: Check the expiry date on the carton before taking a tablet. Do not use DuoPlavin after the expiry date. The expiry date refers to the last day of that month.
- Disposal: Do not dispose of medicines in household waste or down the drain. Return unused or expired DuoPlavin to your pharmacist for safe disposal.
What Does DuoPlavin Contain?
Each DuoPlavin film-coated tablet contains two active substances: clopidogrel 75 mg (as clopidogrel hydrogen sulphate) and acetylsalicylic acid (aspirin) 75 mg, along with inactive excipients used for tablet formation and coating.
Active Ingredients
- Clopidogrel 75 mg (present as clopidogrel hydrogen sulphate 97.875 mg) — a thienopyridine antiplatelet agent
- Acetylsalicylic acid (Aspirin) 75 mg — a non-steroidal anti-inflammatory drug (NSAID) with antiplatelet properties at low doses
Inactive Ingredients (Excipients)
The tablet core contains: microcrystalline cellulose, pregelatinised maize starch, mannitol (E421), hydroxypropylcellulose, macrogol 6000, hydrogenated castor oil, stearic acid, low-substituted hydroxypropylcellulose, and maize starch. The film coating contains: lactose monohydrate, hypromellose (E464), titanium dioxide (E171), triacetin, iron oxide red (E172), carnauba wax, and iron oxide yellow (E172).
DuoPlavin tablets are pink, oval, biconvex film-coated tablets debossed with “C75” and “A75” on one side. They are available in blister packs of 28 or 30 tablets. Not all pack sizes may be marketed in your country.
DuoPlavin contains lactose monohydrate. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine. The tablet also contains hydrogenated castor oil, which may cause stomach upset.
Frequently Asked Questions About DuoPlavin
DuoPlavin is a combination medicine containing clopidogrel (75 mg) and aspirin (75 mg). It is used to prevent atherothrombotic events (such as heart attacks and strokes) in adults who are already taking both clopidogrel and aspirin separately. It is commonly prescribed after acute coronary syndrome, after placement of a coronary stent, or following a recent heart attack. DuoPlavin is a continuation therapy — meaning your doctor will start you on the individual components first, then switch you to DuoPlavin for convenience.
There is no difference in clinical effect. DuoPlavin contains the exact same doses of clopidogrel (75 mg) and aspirin (75 mg) as taking the two medicines separately. The advantage is convenience: one tablet instead of two, which can help some patients remember to take their medication consistently. Studies have shown that reducing pill burden improves medication adherence, which is especially important for dual antiplatelet therapy where missing doses can have serious consequences.
The duration depends on your specific condition. After acute coronary syndrome, dual antiplatelet therapy is generally recommended for 12 months. After coronary stent placement, the minimum is usually 6 months for drug-eluting stents and 1 month for bare-metal stents, though many cardiologists recommend 12 months. In some high-risk patients, treatment may be extended beyond 12 months. In patients at high bleeding risk, a shorter duration (3-6 months) may be considered. Your cardiologist will tailor the duration based on your individual risk profile, balancing the benefit of thrombotic protection against the risk of bleeding.
You should avoid NSAIDs such as ibuprofen and naproxen while taking DuoPlavin, as they significantly increase the risk of gastrointestinal bleeding. Additionally, ibuprofen may competitively block the cardioprotective effect of aspirin if taken before the aspirin dose. Paracetamol (acetaminophen) is generally considered a safer alternative for mild to moderate pain. For more severe pain, discuss options with your doctor. If you need anti-inflammatory treatment, your doctor may consider short-term use with gastroprotective therapy, but this should be carefully supervised.
You should limit alcohol consumption while taking DuoPlavin. Alcohol irritates the stomach lining and can increase the risk of gastrointestinal bleeding, especially in combination with aspirin. Heavy alcohol use also affects liver function, which is important because clopidogrel requires liver enzymes (CYP2C19) for activation. Occasional moderate alcohol consumption (one drink per day for women, up to two for men) is generally considered acceptable, but discuss your individual situation with your doctor.
If you miss a dose and it has been less than 12 hours since your usual time, take it as soon as you remember. If more than 12 hours have passed, skip the missed dose and take the next dose at your regular time. Never take two tablets at once to make up for a missed dose, as this increases bleeding risk. If you frequently forget your medication, consider using a pill organizer, setting a daily phone alarm, or asking your pharmacist about medication reminder services.
References
All medical information in this article is based on internationally recognized guidelines, peer-reviewed research, and evidence-based medicine principles. The following sources were used:
- Yusuf S, Zhao F, Mehta SR, et al. Effects of Clopidogrel in Addition to Aspirin in Patients with Acute Coronary Syndromes without ST-Segment Elevation (CURE Trial). New England Journal of Medicine. 2001;345(7):494-502. doi:10.1056/NEJMoa010746
- Chen ZM, Jiang LX, Chen YP, et al. Addition of Clopidogrel to Aspirin in 45,852 Patients with Acute Myocardial Infarction (COMMIT/CCS-2 Trial). Lancet. 2005;366(9497):1607-1621. doi:10.1016/S0140-6736(05)67660-X
- Byrne RA, Rossello X, Coughlan JJ, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. European Heart Journal. 2023;44(38):3720-3826. doi:10.1093/eurheartj/ehad191
- Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy. Journal of the American College of Cardiology. 2016;68(10):1082-1115. doi:10.1016/j.jacc.2016.03.513
- European Medicines Agency (EMA). DuoPlavin Summary of Product Characteristics (SmPC). Sanofi. Last updated 2024.
- World Health Organization (WHO). WHO Model List of Essential Medicines — 23rd List (2023). Geneva: WHO; 2023.
- Joint Formulary Committee. British National Formulary (BNF). London: BMJ Group and Pharmaceutical Press. Accessed January 2026.
- Bhatt DL, Scheiman J, Abraham NS, et al. ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use. Circulation. 2008;118(18):1894-1909. doi:10.1161/CIRCULATIONAHA.108.191087
About the Medical Editorial Team
This article was written and reviewed by the iMedic Medical Editorial Team, a group of licensed specialist physicians with expertise in cardiology, clinical pharmacology, and evidence-based medicine. Our editorial process follows the GRADE framework for evaluating medical evidence, ensuring that all information meets the highest standards of accuracy and clinical relevance.
iMedic Medical Editorial Team — Specialists in cardiology and clinical pharmacology with documented academic backgrounds and clinical experience.
iMedic Medical Review Board — Independent panel of board-certified physicians who review all content according to ESC, AHA/ACC, and WHO guidelines.
Guideline adherence: ESC Guidelines (2023), AHA/ACC Dual Antiplatelet Therapy Guidelines (2016), WHO Essential Medicines List (2023), British National Formulary (BNF), GRADE evidence framework.
Conflict of interest: None. iMedic receives no pharmaceutical company funding, sponsorship, or advertising revenue. All content is editorially independent.